Skip to main content
. 2020 Aug 15;4(6):1135–1139. doi: 10.1002/jgh3.12408

Table 2.

Response to treatment with sorafenib for unresectable hepatocellular carcinoma

Evaluation (mRECIST/RECIST) mRECIST n (%) (n = 13) RECIST n (%) (n = 13)
Complete response 0 (0) 0 (0)
Partial response 2 (0) 0 (0)
Stable disease 7 (53.8) 9 (69.3)
Progressive disease 4 (30.7) 4 (30.7)
Objective response rate (%) 15.4 0
Disease control rate (%) 69.3 69.3

mRECIST, modified response evaluation criteria in solid tumors.